|
๐
|
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
18 auth.
R. Finn,
J. Crown,
I. Lรกng,
K. Boรฉr,
I. Bondarenko,
Sergey O. Kulyk,
J. Ettl,
Ravi B. Patel,
T. Pintรฉr,
Marcus Schmidt,
...
Y. Shparyk,
A. Thummala,
Nataliya L. Voytko,
C. Fowst,
Xin Huang,
Sindy T. Kim,
S. Randolph,
D. Slamon
|
10 |
2015 |
10
๐
|
|
๐
|
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
18 auth.
M. Cristofanilli,
N. Turner,
I. Bondarenko,
J. Ro,
S. Im,
N. Masuda,
M. Colleoni,
A. DeMichele,
S. Loi,
S. Verma,
...
H. Iwata,
N. Harbeck,
Ke Zhang,
K. Theall,
Yuqiu Jiang,
C. H. Bartlett,
M. Koehler,
D. Slamon
|
10 |
2016 |
10
๐
|
|
๐
|
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
19 auth.
N. Turner,
D. Slamon,
J. Ro,
I. Bondarenko,
S. Im,
N. Masuda,
M. Colleoni,
A. DeMichele,
S. Loi,
S. Verma,
...
H. Iwata,
N. Harbeck,
S. Loibl,
F. Andrรฉ,
K. Theall,
Xin Huang,
C. Giorgetti,
C. H. Bartlett,
M. Cristofanilli
|
9 |
2018 |
9
๐
|
|
๐
|
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
14 auth.
M. Reck,
R. Kaiser,
A. Mellemgaard,
J. Douillard,
S. Orlov,
M. Krzakowski,
J. von Pawel,
M. Gottfried,
I. Bondarenko,
M. Liao,
...
Claudia-Nanette Gann,
J. Barrueco,
B. Gaschler-Markefski,
S. Novello
|
9 |
2014 |
9
๐
|
|
๐
|
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
9 auth.
C. Bokemeyer,
I. Bondarenko,
J. Hartmann,
F. D. Braud,
G. Schuch,
A. Zubel,
...
I. Celik,
M. Schlichting,
P. Koralewski
|
9 |
2011 |
9
๐
|
|
๐
|
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.
10 auth.
M. Reck,
I. Bondarenko,
A. Luft,
P. Serwatowski,
F. Barlesi,
R. Chacko,
...
M. Sebastian,
Haolan Lu,
J. Cuillerot,
T. Lynch
|
9 |
2013 |
9
๐
|
|
๐
|
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
11 auth.
T. Lynch,
I. Bondarenko,
A. Luft,
P. Serwatowski,
F. Barlesi,
R. Chacko,
...
M. Sebastian,
J. Neal,
Haolan Lu,
J. Cuillerot,
M. Reck
|
9 |
2012 |
9
๐
|
|
๐
|
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
18 auth.
J. Robertson,
I. Bondarenko,
E. Trishkina,
M. Dvorkin,
L. Panasci,
A. Manikhas,
Y. Shparyk,
S. Cardona-Huerta,
K. Cheung,
M. Philco-Salas,
...
M. Ruรญz-Borrego,
Z. Shao,
S. Noguchi,
J. Rowbottom,
M. Stuart,
L. Grinsted,
M. Fazal,
M. Ellis
|
8 |
2016 |
8
๐
|
|
๐
|
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
25 auth.
J. Goldman,
M. Dvorkin,
Yuanbin Chen,
N. Reinmuth,
K. Hotta,
D. Trukhin,
G. Statsenko,
M. Hochmair,
M. รzgรผroฤlu,
J. Ji,
M. Garassino,
O. Voitko,
A. Poltoratskiy,
Santiago Ponce,
F. Verderame,
...
L. Havel,
I. Bondarenko,
A. Kaลผarnowicz,
G. Losonczy,
N. Conev,
J. Armstrong,
N. Byrne,
P. Thiyagarajah,
Haiyi Jiang,
L. Paz-Ares
|
8 |
2020 |
8
๐
|
|
๐
|
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
18 auth.
A. Awada,
R. Colomer,
Kenichi Inoue,
I. Bondarenko,
R. Badwe,
G. Demetriou,
Soo-Chin Lee,
A. Mehta,
Sung-Bae Kim,
T. Bachelot,
...
C. Goswami,
S. Deo,
R. Bose,
A. Wong,
Feng Xu,
B. Yao,
R. Bryce,
L. Carey
|
8 |
2016 |
8
๐
|
|
๐
|
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
15 auth.
J. Bergh,
I. Bondarenko,
M. Lichinitser,
A. Liljegren,
R. Greil,
Nataliya L. Voytko,
A. Makhson,
J. Cortรฉs,
A. Lortholary,
J. Bischoff,
...
A. Chan,
S. Delaloge,
Xin Huang,
K. Kern,
C. Giorgetti
|
7 |
2012 |
7
๐
|
|
๐
|
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
13 auth.
M. Aapro,
H. Rugo,
G. Rossi,
G. Rizzi,
M. E. Borroni,
I. Bondarenko,
T. Sarosiek,
C. Oprean,
S. Cardona-Huerta,
V. Lorusso,
...
M. Karthaus,
L. Schwartzberg,
S. Grunberg
|
7 |
2014 |
7
๐
|
|
๐
|
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
102 auth.
S. Qin,
S. Chan,
S. Gu,
Y. Bai,
Z. Ren,
Xiaoyan Lin,
Zhendong Chen,
W. Jia,
Yongdong Jin,
Ya-bing Guo,
Xiaohua Hu,
Z. Meng,
Jun Liang,
Ying Cheng,
Jianping Xiong,
...
H. Ren,
Fan Yang,
W. Li,
Yajin Chen,
Yong Zeng,
A. Sultanbaev,
M. Pazgan-Simon,
M. Pisetska,
D. Melisi,
Dmitriy Ponomarenko,
Yurii Osypchuk,
I. Sinielnikov,
TsaiโSheng Yang,
Xiao Liang,
Chunxia Chen,
Linna Wang,
A. Cheng,
A. Kaseb,
A. Vogel,
Mingxiang Zhang,
Li Xu,
Xianglin Yuan,
Da Li,
Jierer Ying,
Jingdong Zhang,
Tao Zhang,
K. Gu,
Yifu He,
Ping Hao,
D. Jiang,
Shu Zhang,
B. Xing,
Baihong Zhang,
Dong Wang,
Xiaofeng Zhai,
Houjie Liang,
B. Cybulska-Stopa,
M. Dvorkin,
D. Stroyakovskiy,
M. Nechaeva,
C. Yen,
W. Su,
Yen Chen,
I. Bondarenko,
Lin Yang,
W. Fang,
C. Gรณmez-Martรญn,
M. Ryu,
Han-Sang Kim,
Jee-Hyun Kim,
Oleg Zarubenkov,
R. Orlova,
E. Poddubskaya,
N. Fadeeva,
Y. Makarova,
Y. Chao,
Chao-Hung Hung,
Maryna Neffa,
O. Vynnychenko,
Adam M. Burgoyne,
C. Hao,
R. Mohr,
R. Diaz-Beveridge,
Jaime Feliรบ-Batlle,
Antonio Cubillo-Gracian,
A. Lee,
B. Daniele,
L. Antonuzzo,
A. Sangiovanni,
A. Gasbarrini,
M. Scartozzi,
M. Ahn,
S. Oh,
S. Orlov,
H. Harputluoglu,
B. Oksuzoglu,
Chiun Hsu,
K. Rau,
Oleksandr Krechkovskyi,
Vladimir Yareshko,
H. Xiong,
F. Lee,
Yixing Jiang,
A. Gabayan,
Mary Crow,
C. Steenkiste,
G. Verset
|
7 |
2023 |
7
๐
|
